The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | Novel BTK inhibitor acalabrutinib shows promise in CLL
A novel BTK inhibitor, acalabrutinib, is showing promise in the early clinical trial stages for chronic lymphocytic leukemia (CLL). Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Susan O’Brien, MD, of the University of California, Irvine, CA, discusses the benefits of acalabrutinib over ibrutinib and why this may be. Prof. O’Brien highlights the main studies of this agent for CLL, including as a monotherapy (ACE-CL-001; NCT02029443) and in combination with ACP-319 (ACE-CL-002; NCT02157324) in the relapsed/refractory setting, and in the frontline setting in combination with obinutuzumab (ACE-CL-003; NCT02296918).
